WASHINGTON – Two years after the Supreme Court tossed out a challenge to the widely used abortion drug mifepristone, the justices must again decide whether access should be restricted.
In emergency appeals filed May 2, drug makers Danco Laboratories and GenBioPro asked the court to immediately pause a lower court ruling limiting access.
“The Supreme Court must reject this unfounded and baseless attack on an essential medication," GenBioPro CEO Evan Masingill said in a statement.
The conservative 5th U.S. Circuit Court of Appeals on May 1 temporarily reinstated a Food and Drug Administration requirement that doctors prescribe the drug only after an in-person exam. The three-judge panel did so in response to a challenge from Louisiana to the elimination of that requirement by the Biden administration.
0 Comments